Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa first-in-human study of monthly subcutaneous cariprazine depot versus oral cariprazine
MOH_2025-05-29_014120Phase 2Recruiting
- Sponsor
- Mapi Pharma
- Start
- Apr 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cariprazine in schizophrenia, bipolar I disorder and major depressive disorder (MDD), sponsored by Mapi Pharma. Started Apr 2025; status: recruiting.
02
Drugs
cariprazine
03
Conditions
schizophreniabipolar I disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on MOH_2025-05-29_014120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-05-29_014120.